Wuhan YZY Biopharma Co EBIT

The latest EBIT for 2496.HK is $-45M as of June 2026. That compares with $-75M in the prior-year period — up 39.5% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Wuhan YZY Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, 2496.HK's EBIT moved from $-75M to $-45M — a 39.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Wuhan YZY Biopharma Co's operating scale or balance-sheet position.

Against Healthcare companies, 2496.HK currently prints $-45M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Wuhan YZY Biopharma Co's growth, margins, and balance sheet.

A EBIT figure of $-45M for 2496.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 2496.HK's EBIT ($-45M), review year-over-year change from $-75M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.